Skip to main content
Top
Published in: Calcified Tissue International 1/2004

01-01-2004 | Laboratory Investigations

Effects of Weekly Administrations of Alendronate+Clodronate on Young Mouse Tibia: Localized Action at the Proximal Growth Plate

Authors: Y. Monma, H. Funayama, H. Mayanagi, Y. Endo

Published in: Calcified Tissue International | Issue 1/2004

Login to get access

Abstract

Alendronate (A), a typical aminobisphosphonate (aminoBP), has a strong bone-resorption-inhibitory activity (BRIA). However, like other aminoBPs it has inflammatory side effects. In contrast, the BRIA of clodronate (C), a non-aminoBP, is much weaker, and in animal experiments it suppresses aminoBP-induced inflammatory reactions. In the present study, we examined the effects of weekly administrations of A (1.6 µmol/kg) + C (160 µmol/kg) on the tibias in young mice and compared them to those induced by A or C alone. Radiophotography showed that A increased bone density at a selective site in the tibia. Indeed, one week after the final injection of A (given alone), clear sclerotic lines (tentatively called BP-lines) were visible at sites corresponding to the location of the growth plate at the time of the each injection. C also produced BP-lines, although they were weaker than those produced by A. Combined administration of A and C produced similar BP-lines as seen in mice given A alone. These results together with other physicochemical effects of A on the tibia suggest that (1) each injection of A and C inhibits bone resorption selectively and transiently at the tibial growth plate in young mice, although minor effects on other sites cannot be excluded, and (2) the combination of A and C keeps still a strong BRIA. Our findings may suggest a strategy for the prevention or reduction of some inflammatory side effects of A or other aminoBPs.
Literature
1.
go back to reference Rodan, GA, Fleisch, HA 1996Bisphosphonates: mechanism of action.J Clin Invest9726922696PubMed Rodan, GA, Fleisch, HA 1996Bisphosphonates: mechanism of action.J Clin Invest9726922696PubMed
2.
go back to reference Bonjour, JP, Rizzoli, R, Ammann, P, Chevalley, T 1994Bisphosphonates in clinical medicine.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam205264 Bonjour, JP, Rizzoli, R, Ammann, P, Chevalley, T 1994Bisphosphonates in clinical medicine.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam205264
3.
go back to reference Geddes, AD, D’Souza, SM, Ebentino, FH, Kenneth, JI 1994Bisphosphonates: structure-activity relationships and therapeutic implications.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam265306 Geddes, AD, D’Souza, SM, Ebentino, FH, Kenneth, JI 1994Bisphosphonates: structure-activity relationships and therapeutic implications.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam265306
4.
go back to reference Glorieux, FH, Bishop, NJ, Plotkin, H, Chabot, G, Lanoue, G, Travers, R 1998Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.N Engl J Med339947952 Glorieux, FH, Bishop, NJ, Plotkin, H, Chabot, G, Lanoue, G, Travers, R 1998Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.N Engl J Med339947952
5.
go back to reference Adami, S, Bhalla, AK, Dorizzi, R, Montesani, F, Rosini, S, Salvagno, G, Lo Cascio, V 1987The acute phase response after bisphosphonate administration.Calcif Tissue Int41326331PubMed Adami, S, Bhalla, AK, Dorizzi, R, Montesani, F, Rosini, S, Salvagno, G, Lo Cascio, V 1987The acute phase response after bisphosphonate administration.Calcif Tissue Int41326331PubMed
6.
go back to reference Sauty, A, Pecherstorfer, M, Zimmer-Roth, I, Fioroni, P, Juillerat, L, Markert, M, Ludwig, H, Leuenberger, P, Burckhardt, P, Thiébaud, D 1996Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy.Bone18133139CrossRefPubMed Sauty, A, Pecherstorfer, M, Zimmer-Roth, I, Fioroni, P, Juillerat, L, Markert, M, Ludwig, H, Leuenberger, P, Burckhardt, P, Thiébaud, D 1996Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy.Bone18133139CrossRefPubMed
7.
go back to reference Thiébaud, D, Sauty, A, Burckhardt, P, Leuenberger, P, Sitzler, L, Green, JR, Kandra, A, Zieschang, J, Ibarra de Palacios, P 1997An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.Calcif Tissue Int61386392CrossRefPubMed Thiébaud, D, Sauty, A, Burckhardt, P, Leuenberger, P, Sitzler, L, Green, JR, Kandra, A, Zieschang, J, Ibarra de Palacios, P 1997An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.Calcif Tissue Int61386392CrossRefPubMed
9.
go back to reference Macarol, V, Frauenfelder, FT 1994Pamidronate disodium and possible ocular adverse drug reactions.Am J Ophthamol118220224 Macarol, V, Frauenfelder, FT 1994Pamidronate disodium and possible ocular adverse drug reactions.Am J Ophthamol118220224
10.
go back to reference Fleisch, HA 1997Bisphosphonates: preclinical aspects and use in osteoporosis.Anal Med295662 Fleisch, HA 1997Bisphosphonates: preclinical aspects and use in osteoporosis.Anal Med295662
11.
go back to reference Mönkkönen, J, Koponen, HM, Ylitalo, P 1989Comparison of the distribution of three bisphosphonates in mice.Pharmacol Toxicol65294298 Mönkkönen, J, Koponen, HM, Ylitalo, P 1989Comparison of the distribution of three bisphosphonates in mice.Pharmacol Toxicol65294298
12.
go back to reference Endo, Y, Nakamura, N, Kikuchi, T, Shinoda, H, Takeda, K, Nitta, Y, Kumagai, K 1993Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int52248254PubMed Endo, Y, Nakamura, N, Kikuchi, T, Shinoda, H, Takeda, K, Nitta, Y, Kumagai, K 1993Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int52248254PubMed
13.
go back to reference Nakamura, M, Ando, T, Masataka, A, Kumagai, K, Endo, Y 1996Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.Br J Pharmacol119205212PubMed Nakamura, M, Ando, T, Masataka, A, Kumagai, K, Endo, Y 1996Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.Br J Pharmacol119205212PubMed
14.
go back to reference Sugawara, S, Shibazaki, M, Takada, H, Kosugi, K, Endo, Y 1998Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice.Br J Pharmacol125735740PubMed Sugawara, S, Shibazaki, M, Takada, H, Kosugi, K, Endo, Y 1998Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice.Br J Pharmacol125735740PubMed
15.
go back to reference Funayama, H, Mayanagi, H, Takada, H, Endo, Y 2000Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate.Arch Oral Biol45787795CrossRefPubMed Funayama, H, Mayanagi, H, Takada, H, Endo, Y 2000Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate.Arch Oral Biol45787795CrossRefPubMed
16.
go back to reference Yamaguchi, K, Motegi, K, Iwakura, Y, Endo, Y 2000Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.Br J Pharmacol13016461654PubMed Yamaguchi, K, Motegi, K, Iwakura, Y, Endo, Y 2000Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.Br J Pharmacol13016461654PubMed
17.
go back to reference Endo, Y, Shibazaki, M, Nakamura, M, Kosugi, H 1999Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.Br J Pharmacol126903910PubMed Endo, Y, Shibazaki, M, Nakamura, M, Kosugi, H 1999Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.Br J Pharmacol126903910PubMed
18.
go back to reference Kasting, GB, Francis, MD 1992Retention of etidronate in human, dog, and rat.J Bone Miner Res7513522 Kasting, GB, Francis, MD 1992Retention of etidronate in human, dog, and rat.J Bone Miner Res7513522
19.
go back to reference Devogelaer, JP, Malghem, J, Maldague, B, Nagant de Deuxchaisnes, D 1987Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.Skeletal Radiol16360363PubMed Devogelaer, JP, Malghem, J, Maldague, B, Nagant de Deuxchaisnes, D 1987Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.Skeletal Radiol16360363PubMed
20.
go back to reference Sato, M, Grasser, W, Endo, N, Akins, R, Simmons, H, Thompson, DD, Golub, E, Rodan, GA 1991Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure.J din Invest8820952105 Sato, M, Grasser, W, Endo, N, Akins, R, Simmons, H, Thompson, DD, Golub, E, Rodan, GA 1991Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure.J din Invest8820952105
21.
go back to reference Amin, D, Cornell, SA, Gustafson, SK, Needle, SJ, Ullrich, JW, Bilder, GE, Perrone, MH 1992Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.J Lipid Res3316571663PubMed Amin, D, Cornell, SA, Gustafson, SK, Needle, SJ, Ullrich, JW, Bilder, GE, Perrone, MH 1992Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.J Lipid Res3316571663PubMed
22.
go back to reference Amin, D, Cornell, SA, Perrone, MH, Bilder, GE 19961-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.Drug Res46759762 Amin, D, Cornell, SA, Perrone, MH, Bilder, GE 19961-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.Drug Res46759762
23.
go back to reference Fisher, JE, Rogers, MJ, Halasy, JM, et al. 1999Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro.Proc Natl Acad Sci USA96133138CrossRefPubMed Fisher, JE, Rogers, MJ, Halasy, JM,  et al. 1999Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro.Proc Natl Acad Sci USA96133138CrossRefPubMed
24.
go back to reference Van Beek, E, Löwik, C, Van Der Pluijm, G, Papapoulos, S 1999The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates.J Bone Miner Res14722729 Van Beek, E, Löwik, C, Van Der Pluijm, G, Papapoulos, S 1999The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates.J Bone Miner Res14722729
25.
go back to reference Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun255491494PubMed Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun255491494PubMed
26.
go back to reference Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.Biochem Biophys Res Commun264108111CrossRefPubMed Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.Biochem Biophys Res Commun264108111CrossRefPubMed
27.
go back to reference Martin, MB, Arnold, W, Heath, HT, Urbina, JA, Oldfield, E 1999Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.Biochem Biophys Res Commun263754758CrossRefPubMed Martin, MB, Arnold, W, Heath, HT, Urbina, JA, Oldfield, E 1999Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.Biochem Biophys Res Commun263754758CrossRefPubMed
28.
go back to reference Keller, K, Fliesler, SJ 1999Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway.Biochem Biophys Res Commun266560563CrossRefPubMed Keller, K, Fliesler, SJ 1999Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway.Biochem Biophys Res Commun266560563CrossRefPubMed
29.
go back to reference Frith, JC, Mönkkönen, J, Blackburn, GM, Russel, RG, Rogers, MJ 1997Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1213581367 Frith, JC, Mönkkönen, J, Blackburn, GM, Russel, RG, Rogers, MJ 1997Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1213581367
30.
go back to reference Auriola, S, Frith, JC, Rogers, MJ, Koivuniemi, A, Mönkkönen, J 1997Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.J Chromatogr B704187195CrossRef Auriola, S, Frith, JC, Rogers, MJ, Koivuniemi, A, Mönkkönen, J 1997Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.J Chromatogr B704187195CrossRef
31.
go back to reference Halasy-Nagy, JM, Rodan, GA, Reszka, AA 2001Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.Bone29553559CrossRefPubMed Halasy-Nagy, JM, Rodan, GA, Reszka, AA 2001Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.Bone29553559CrossRefPubMed
32.
go back to reference Suri, S, Mönkkönen, J, Taskinen, M, Pesonen, J, Blank, MA, Phipps, RJ, Rogers, MJ 2001Nitrogen-containing bisphosphonates induce apoptosis of Cao-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.Bone29336343CrossRefPubMed Suri, S, Mönkkönen, J, Taskinen, M, Pesonen, J, Blank, MA, Phipps, RJ, Rogers, MJ 2001Nitrogen-containing bisphosphonates induce apoptosis of Cao-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.Bone29336343CrossRefPubMed
33.
go back to reference Reszka, AA, Halasy-Nagy, J, Rodan, GA 2001Nitrogen-bisphosphonate block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in keratinocyte model for esophageal irritation.Mol Pharmacol59193202PubMed Reszka, AA, Halasy-Nagy, J, Rodan, GA 2001Nitrogen-bisphosphonate block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in keratinocyte model for esophageal irritation.Mol Pharmacol59193202PubMed
34.
go back to reference Ayada, K, Oguri, S, Yamaguchi, K, Kumagai, K, Endo, Y 2003Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs.Eur J Pharmacol4606369CrossRefPubMed Ayada, K, Oguri, S, Yamaguchi, K, Kumagai, K, Endo, Y 2003Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs.Eur J Pharmacol4606369CrossRefPubMed
Metadata
Title
Effects of Weekly Administrations of Alendronate+Clodronate on Young Mouse Tibia: Localized Action at the Proximal Growth Plate
Authors
Y. Monma
H. Funayama
H. Mayanagi
Y. Endo
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2004
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-2156-5

Other articles of this Issue 1/2004

Calcified Tissue International 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.